

BÖLÜM 32

Kemo-Radyoterapinin Semen Parametrelerine Etkisi

Halenur BOZDAĞ¹

GİRİŞ

Günümüzde uygulanan kemo-radyoterapi uygulamalarının gonadlar üzerine toksik etkileri ve neoplastik hastalığın kendisinin fertilité üzerine olumsuz sonuçları nedeniyle gonadoksisiste ve fertilitéde bozulma kanserden kurtulan hastalar için en yaygın sorunlardır (1). Etkili radyoterapi, kemoterapi ve cerrahi tedavi protokolleri sayesinde malign lenfo proliferatif hastalıkların %80-90'ı tedavi edilebilmekte (2,3) düşük riskli testis kanser hastalarının 5 yıllık sağ kalım oranı %90'ın üzerine ulaşmaktadır (4). Kanser hastalarının, hayatta kalma süreleri önemli ölçüde uzamış, genç yaşta kanserden kurtulan reproduktif dönemdeki erkeklerin sayısı, çarpıcı biçimde artmıştır.

Kanser hastalarında hastalığın kendisi semen parametrelerini olumsuz yönde etkiler. Herhangi bir tedaviye başlamadan önce semen parametrelerinde bozulma sağlıklı erkeklere göre daha sıktır. Malign neoplazmi olan hastaların üçte birinde spermatogenez bozulur ve tanı esnasında şiddetli oligospermi veya azospermi bulgusu görülür (5). Bir çalışmada, kanser tanısı alan ve tedavi öncesi sperm bankasına semen bırakan erkeklerin %64'ünde tedavi öncesi parametreler anormal bulunmuş. Hastaların %12.2'si azospermi nedeni ile sperma

¹ Dr. Öğr. Üyesi, Bahçeşehir Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum AD., halenurbozdag@hotmail.com

KAYNAKLAR

1. Dohle GR. Male infertility in cancer patients: Review of the literature. *Int. Urol.* 2010 Apr;17 (4):327-31.
2. Raemaekers J, Kluijn-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke M, Henry-Amar M, Carde P. The Achievements of the EORTC. Lymphoma Group. European Organisation for Research and Treatment of Cancer. *Eur. Cancer.* 2002; 38, S107–113.
3. Sieber M, Rueffer U, Josting A, Diehl V. Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group. *Ann Oncol.* 1999; 10, 23–29.
4. Mead GM, Stenning SP. The International Germ Cell Consensus Classification: new prognostic factor-based staging classification for metastatic germ cell tumours. *Clin Oncol (R Coll Radiol).* 1997; 9, 207–220.
5. Crha I, Ventruba P, Zakova J, Huser M, Kubesova B, Hudecek R, Jarkovsky J. Survival an infertility treatment in male cancer patients after sperm banking. *Fertil Steril.* 2009 Jun;91 (6):2344-2348.
6. Van Casteren NJ, Boellaard WP, Romijn JC, Dohle GR. Gonadal dysfunction in male cancer patients before cytotoxic treatment. *Int. Androl.* 2010 Feb;33 (1):73-79.
7. Vomstein, K., Reiser, E., Pinggera, G. M., Toerzsoek, P., Deininger, S., Kriesche, T., Toth, B. Sperm banking before gonadotoxic treatment: is it worth the effort?. *Asian Journal of Andrology* 2021;23 (5), 490.
8. Chung K, Irani J, Efyomow B, Blasco L, Patrizio P. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. *Eur. Obstet Gynecol Reprod Biol* 2004;113 (Suppl 1):7–11.
9. Agarwal A, Allamaneni SS. Disruption of spermatogenesis by the cancer disease process.. *Natl Cancer Inst Monogr* 2005;34:9–12.
10. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis.. *Urol.* 2005, 174,1819-1822.
11. Sabanegh ES Jr, Ragheb AM. Male fertility after cancer. *Urology*, 2009, 73, 225-231.
12. Stumpp T, Freymüller E, Miraglia SM. Sertoli cell function in albino rats treated with etoposide during prepubertal phase. *Histochem Cell Biol* 2006; 126, 353–361
13. Huleihel M, Lunenfeld E. Regulation of spermatogenesis by paracrine/autocrine testicular factors. *Asian. Androl*, 2004;6, 259–268
14. Holstein A-F, Schulze W, Davidoff M. Understanding spermatogenesis is prerequisite for treatment. *Reproductive Biology and Endocrinology.* 2003;1 (1):107.
15. Monsees TK, Franz M, Gebhardt S, Winterstein U, Schill WB, Hayatpour J. Sertoli cells as target for reproductive hazards. *Andrologia*, 2000; 32, 239–246.
16. López Andreu JA, Fernández PJ, Ferrís. Tortajada J, Navarro I, Rodríguez-Ineba A, Antonio P, et al. Persistent altered spermatogenesis in long-term childhood cancer survivors. *Pediatr Hematol Oncol* 2000;17:21-30.
17. KURTMAN, C. Radyobiyojojide hücre siklusu, 5r ve hasar. *Ankara Sağlık Hizmetleri Dergisi* 2018;17 (1), 25-27.
18. Dillon KE, Gracia CR. Pediatric and Young Adult Patients and Oncofertility. *Current Treatment Options in Oncology.* 2012;13 (2):161-173.
19. Vogin G, Foray N. The law of Bergonié and Tribondeau: nice formula for. first approximation. *Int. RadiatBiol.* 2013 Jan;89 (1):2-8.

20. Stewart, F.A., Akleyev, A.V., Hauer-Jensen, M., Hendry, J.H., Kleiman, N.J., Macvittie, T.J., Aleman, B.M., Edgar, A.B., Mabuchi, K., Muirhead, C.R. and Shore, R.E. ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs—threshold doses for tissue reactions in radiation protection context. *Annals of the ICRP* 2012;41 (1-2), pp.1-322
21. Caldeira-Brant, A. L., Martinelli, L. M., Marques, M. M., Reis, A. B., Martello, R., Almeida, F. R. C. L., & Chiarini-Garcia, H. subpopulation of human Adark spermatogonia behaves as the reserve stem cell. *Reproduction* 2020;159 (4), 437-451.
22. Clifton DK, Bremner WJ. The effect of testicular X-irradiation on spermatogenesis in man.. comparison with the mouse.. *Androl.* 1983; 4:387-92.
23. De Felice, F., Musio, D. And Tombolini, V., Osteoradionecrosis and intensity modulated radiation therapy: an overview. *Critical reviews in oncology/hematology* 2016.;107, pp.39-43.
24. Wdowiak, A., Skrzypek, M., Stec, M., and Panasiuk, L. Effect of ionizing radiation on the male reproductive system. *Ann Agric Environ Med* 2019;26 (2), pp.210-216.
25. Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI. Adverse effects of treatment: gonadal dysfunction. In: DeVita VT, Hellman S, Rosenberg SA, editors. *Cancer: principles and practice of oncology*. ed. 7. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 2560-74.
26. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery.. *Nat Cancer Inst Monogr* 2005;34:12-7
27. Ståhl O, Eberhard J, Jepson K, et al. Sperm DNA integrity in testicular cancer patients. *Hum Reprod* 2006;21: 3199-3205.
28. Izard, M.A., Leydig cell function and radiation:. review of the literature. *Radio therapy and Oncology* 1995;34 (1), pp.1-8.
29. Lu lu Cheburakov ,O.P. Cheburakova. Disorders of spermatogenesis in people working at the clean-up of the Chernobyl nuclear power plant accident. *Radiat sionnaia biologiiia, radioecologia* 1993;33 (6), pp.771-774.
30. Ash, 1980 Ash, P., The influence of radiation on fertility in man. *The British journal of radiology* 1980;53 (628), pp.271-278.
31. Wallace, W. H. B., Anderson, R. A., Irvine, D. S. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *The lancet oncology* 2005;6 (4), 209-218.
32. Chemes HE. Infancy is not. quiescent period of testicular development. *Int. J. Androl.* 2001;24: 2-7.
33. Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogonial renewal. *Physiol Rev* 1972;52: 198-236.
34. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. *Fertil Steril* 1997;68:1-5.
35. Meistrich ML. Relationship between spermatogonial stem cell survival and testis function after cytotoxic therapy. *Br. Cancer Suppl* 1986;7:89-101
36. Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency.. *Clin Oncol* 1999;17:1493-8.
37. Osterberg EC, Ramasamy R, Masson P, Brannigan RE. Current practices in fertility preservation in male cancer patients. *Urol Ann* 2014;6:13-7. 39.
38. Generoso WM, Witt KL, Cain KT, Hughes L, Cacheiro NL, Lockhart AM, et al. Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. *Mutat Res* 1995;345:167-80.

39. Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. *Eur. Obstet Gynecol Reprod Biol.* 2004;113 Suppl 1:S2-6.
40. Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz LI. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. *Cancer* 1992;70:2703-12
41. Hermann BP, Sukhwani M, Lin CC, Sheng Y, Tomko J, Rodriguez M, et al. Characterization, cryopreservation, and ablation of spermatogonial stem cells in adult rhesus macaques. *Stem Cells* 2007;25:2330-8.
42. Choudhury RC, Jagdale MB, Misra S. Potential transmission of the cytogenetic effects of cisplatin in the male germline cells of Swiss mice.. *Chemother* 2000;12:352-9.
43. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers.. *Clin Oncol* 1997;15:239-45.
44. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. *Hum Reprod Update* 2001; 7: 394-403
45. Joblom T, Parvinen M, Lahdetie J. Stage-specific DNA synthesis of rat spermatogenesis as an indicator of genotoxic effects of vinblastine, mitomycin. and ionizing radiation on rat spermatogonia and spermatocytes. *Mutat Res* 1995; 331: 181- 90.
46. Albanese R. Mammalian male germ cell cytogenetics. *Mutagenesis* 1987; 2: 79-85.
47. Liang JC, Sherron DA, Johnston D. Lack of correlation between mutagen-induced chromosomal univalency and aneuploidy in mouse spermatocytes. *Mutat Res* 1986.
48. PP Van Buul, JH Goudzwaard. Bleomycin-induced structural chromosomal aberrations in spermatogonia and bone-marrow cells of mice. *Mutat Res* 1980; 69: 319-24.
49. Thomson AB, Wallace WH. Treatment of paediatric Hodgkin's disease.. balance of risk. *Eur. Cancer* 2002;38 (4):468-77.
50. Bokemeyer C, Schmoll HJ, Van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. *Ann Hematol* 1994; 68:105-10.
51. Pryzant RM, Meistrich ML, Wilson G, Brown B, McLaughlin P. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas.. *Clin Oncol* 1993;11:239-47
52. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.. *Clin Oncol.* 1997; 15:3488-95.
53. MF da Cunha, ML Meistrich, MM Haq, LA Gordon., J Wyrobek. Temporary effects of AMSA [4' (9-acridinylamino) methanesulfon-m-anisidide] chemotherapy on spermatogenesis. *Cancer.* 1982; 49:2459-62.
54. Maltaris, T., Koelbl, H., Seufert, R., Kiesewetter, F, Beckmann, M.W., Mueller, A. and Dittrich, R. Gonadal damage and options for fertility preservation in female and male cancer survivors. *Asian journal of andrology* 2006;8 (5), pp.515-533.
55. Biedka, M., Kuzba-Kryszak, T., Nowikiewicz, T. and Zyromska, A. Fertility impairment in radiotherapy. *Contemporary Oncology*2016;20 (3), p.199.
56. Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. *Radiat Res* 1974; 59:665-78.
57. Paulsen, CA. The study of radiation effects on the human testis: including histologic, chromosomal and hormonal aspects. Final progress report of AEC contract AT (45-1)-2225, Task Agreement 6. U.S. Department of Energy. 1973. RLO-2225-2; p. 1-36.

58. Meistrich ML, van Beek MEAB. Radiation sensitivity of the human testis. *Adv Radiat Biol.* 1990; 14:227–68.
59. Dubey P, Wilson G, Mathur KK, Hage ter FB, Fuller LM, Ha CS, et al. Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine and prednisone (NOVP). *Int. Radiat Oncol Biol Phys.* 2000; 46:609–17.
60. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. *Blood.* 1996; 87:3045–52.
61. Jacob A, Barker H, Goodman A, Holmes J. Recovery of spermatogenesis following bone marrow transplantation. *Bone Marrow Transplant.* 1998; 22:277–9.
62. Marmor D, Grob-Menendez F, Duyck F, Delafontaine D. Very late return of spermatogenesis after chlorambucil therapy: Case reports. *Fertil Steril.* 1992; 58:845–6.
63. Preti A, Hagemester FB, McLaughlin P, Swan F, Redriguez A, Pesa P, et al. Hodgkin's disease with mediastinal mass greater than 10 cm: Results of four different treatment approaches. *Ann Oncol.* 1994;. (Suppl. 2):S97–S100.
64. Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. *Lancet* 1975;2: 156-7.
65. Hsiao W, Stahl PJ, Osterberg EC, Nejat E, Palermo GD, Rosenwaks Z, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience.. *Clin Oncol.* 2011; 29:1607–11.
66. Silber SJ, Nagy Z, Devroey P, Tournaye H, Van Steirteghem AC. Distribution of spermatogenesis in the testicles of azoospermic men: the presence or absence of spermatids in the testes of men with germinal failure. *Hum Reprod.* 1997; 12:2422–8.
67. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA Cancer. Clin.* 2007, 57, 43–66 .
68. Bray F, Richiardi L, Ekblom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. *Int. Cancer.* 2006;118, 3099–3111.
69. Gandini L, Sgro L, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. *Hum Reprod* 2006;21:2882–9.
70. Ishikawa T, Kamidono S, Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. *Urology*, 2004, 63, 137–140
71. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: long-term survey. *Andrologia* 1995;27:99–106.
72. Tal R, Botchan A, Hauser R, Yogev L, Paz G, Yavetz H. Follow-up of sperm concentration and motility in patients with lymphoma. *Hum Reprod.* 2000;15 (9): 1985–1988 .
73. van der Kaaij MA, Heutte N, Le Stang N, Raemaekers JM, Simons AH, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Kluin-Nelemans HC, Henry-Amar M, European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group, Groupe d'Etude des Lymphomes de l'Adulte. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.. *Clin Oncol.* 2007;25:2825–32
74. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. *Bone Marrow Transplant* 2002;30:447–51.